Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) for the reporting period of March 6, 2015. The registrant is a Delaware corporation with principal executive offices in Petaluma, CA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Delisting Notice: On March 6, 2015, the company received notice from NASDAQ that it failed to comply with Listing Rule 5550(a)(2) for 30 consecutive business days due to a minimum bid price below $1.00 per share.
- Compliance Period: NASDAQ granted a 180-day compliance period ending September 2, 2015, to regain compliance.
- Trading Status: The notice has no immediate effect on the listing or trading of the company's common stock.
Outlook, Risks, and Management Commentary
Management intends to cure the bid price deficiency by effecting a reverse stock split if necessary. There is no assurance that the company will be able to regain compliance with the listing rule. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to various risks.
Investor Verification Checklist
- Verify the current closing bid price of the common stock to assess proximity to the $1.00 threshold.
- Monitor upcoming shareholder meetings or filings for proposals regarding a reverse stock split.
- Review the company's most recent Form 10-K for detailed financial health and liquidity positions not included in this 8-K.
- Confirm the company's status on the NASDAQ exchange to ensure no further delisting actions have been taken.